- Enrichment of TP53 alterations within GCB-like DNA subclassifications of diffuse large B-cell lymphoma after transition from de-novo to relapsed or refractory disease
-
Lund S, Ngisa V, Weber K, Rutz A, Guidinger J, Hartert KT
- KMID: 2530885
- Blood Res.
- 2022 Jun;57(2):164-169.
- doi: 10.5045/br.2022.2022052
-
- CITED
-
- Close
- SHARE
-
- Close
- Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease
-
Liam CCK, Boo YL, Chong SL, Sathar J, Ong TC, Tan SM
- KMID: 2530883
- Blood Res.
- 2022 Jun;57(2):158-161.
- doi: 10.5045/br.2022.2020305
-
- CITED
-
- Close
- SHARE
-
- Close
- An infant with severe hemophilia A with intracranial hemorrhage mistaken for child abuse: a case report
-
Youn JW, Shim YJ, Byun JC, Kwon SM
- KMID: 2530887
- Blood Res.
- 2022 Jun;57(2):169-171.
- doi: 10.5045/br.2022.2022073
-
- CITED
-
- Close
- SHARE
-
- Close
- A rare case of primary plasma cell leukemia exhibiting the small-cell variant of plasma cells
-
Kim JA, Shin WY, Kim J, Bang HI, Yoon SY, Park R
- KMID: 2530884
- Blood Res.
- 2022 Jun;57(2):161-164.
- doi: 10.5045/br.2022.2022059
-
- CITED
-
- Close
- SHARE
-
- Close
- Smudge cells in CD200+,TP53 mutated leukemic mantle cell lymphoma
-
Jain P, Han X, Wang M, Tang G
- KMID: 2530869
- Blood Res.
- 2022 Jun;57(2):85-85.
- doi: 10.5045/br.2022.2020113
-
- CITED
-
- Close
- SHARE
-
- Close
- Chronic myeloid leukemia: a type of MPN
-
Samad MA, Mahboob E, Mansoor H
- KMID: 2530872
- Blood Res.
- 2022 Jun;57(2):95-100.
- doi: 10.5045/br.2022.2021173
This review article classifies chronic myeloid leukemia (CML) based on cytogenetic analyses and different mutations detected in CML patients. The use of advanced technologies, such as karyotyping, fluorescent in situ... -
- CITED
-
- Close
- SHARE
-
- Close
- The impact of nucleic acid testing as a blood donor screening method in transfusion-associated hepatitis C among children with bleeding disorders in Indonesia: a single-center experience
-
Chozie NA, Satiti MA, Sjarif DR, Oswari H, Ritchie NK
- KMID: 2530877
- Blood Res.
- 2022 Jun;57(2):129-134.
- doi: 10.5045/br.2022.2021219
Background Children with bleeding disorders, such as hemophilia and von Willebrand disease (VWD), have an increased risk of acquiring transfusion-transmitted infections (TTI). Screening methods to exclude blood donations that are at... -
- CITED
-
- Close
- SHARE
-
- Close
- Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis
-
Alsharidah AS
- KMID: 2530873
- Blood Res.
- 2022 Jun;57(2):101-105.
- doi: 10.5045/br.2022.2021204
Vascular complications lead to morbidity and mortality in patients with diabetes. Diabetic nephropathy (DN) is one of the main life-threatening problems for these patients, as it is the main cause... -
- CITED
-
- Close
- SHARE
-
- Close
- Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8+ T-cells despite immune checkpoint signaling
-
Greenbaum AM, Fromm JR, Gopal AK, Houghton AM
- KMID: 2530875
- Blood Res.
- 2022 Jun;57(2):117-128.
- doi: 10.5045/br.2022.2021145
Background B-cell non-Hodgkin lymphomas (NHL) are hematologic malignancies that arise in the lymph node. Despite this, the malignant cells are not cleared by the immune cells present. The failure of anti-tumor immunity... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk
-
Wo S, Levavi H, Mascarenhas J, Kremyanskaya M, Navada S, Bar-Natan M, Kim SS
- KMID: 2530878
- Blood Res.
- 2022 Jun;57(2):135-143.
- doi: 10.5045/br.2022.2021163
Background Blinatumomab has demonstrated efficacy in minimal residual disease (MRD) positive and relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) by inciting rapid and sustained B-cell depletion. Methods Owing to its effect on B-cells, blinatumomab... -
- CITED
-
- Close
- SHARE
-
- Close
- Multidisciplinary supportive care in systemic light chain amyloidosis
-
Maroun BZ, Allam S, Chaulagain CP
- KMID: 2530874
- Blood Res.
- 2022 Jun;57(2):106-116.
- doi: 10.5045/br.2022.2021227
The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying... -
- CITED
-
- Close
- SHARE
-
- Close
- Favorable outcomes with durable chimerism after hematopoietic cell transplantation using busulfan and fludarabine-based reduced-intensity conditioning for pediatric patients with hemophagocytic lymphohistiocytosis
-
Suh JK, Koh YK, Kang SH, Kim H, Choi ES, Koh KN, Im HJ
- KMID: 2530881
- Blood Res.
- 2022 Jun;57(2):152-157.
- doi: 10.5045/br.2022.2022047
Background The incorporation of a reduced-intensity conditioning (RIC) regimen in hematopoietic cell transplantation (HCT) for patients with hemophagocytic lymphohistiocytosis (HLH) has decreased early mortality but is associated with a high rate... -
- CITED
-
- Close
- SHARE
-
- Close
- Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia
-
Chueh HW, Hwang SM, Shim YJ, Lee JM, Park HS, Lee JH, Nam Y, Kim N, Jung HL, Choi HS, on behalf of Korean RBC Disorder Working Party
- KMID: 2530870
- Blood Res.
- 2022 Jun;57(2):86-94.
- doi: 10.5045/br.2022.2021224
Although the prevalence of hereditary hemolytic anemia (HHA) is relatively low in Korea, it has been gradually increasing in recent decades due to increment in the proportions of hemoglobinopathies from... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
-
Ahn SY, Son SK, Lee GH, Kim I, Cheong JW, Lee WS, Kim BS, Jo DY, Jung CW, Seong CM, Lee JH, Yuh YJ, Kim MK, Ryoo HM, Park MR, Cho SH, Kim HG, Zang DY, Park J, Kim H, Lee S, Kim SH, Chang MH, Lee HS, Choi CW, Kwon J, Lim SN, Oh SJ, Joo I, Kim DW
- KMID: 2530879
- Blood Res.
- 2022 Jun;57(2):144-151.
- doi: 10.5045/br.2022.2021137
Background Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This... -
- CITED
-
- Close
- SHARE
-
- Close
